Zobrazeno 1 - 10
of 14
pro vyhledávání: '"Christoph Konigs"'
Autor:
Jan Blatný, Jan Astermark, Cristina Catarino, Gerry Dolan, Karin Fijnvandraat, Cédric Hermans, Katharina Holstein, Víctor Jiménez-Yuste, Robert Klamroth, Michelle Lavin, Peter J. Lenting, Sébastien Lobet, Maria Elisa Mancuso, Jayashree Motwani, James S. O’Donnell, Christoph Königs
Publikováno v:
Therapeutic Advances in Hematology, Vol 15 (2024)
Over recent decades, management of people with hemophilia (PwH) has been greatly improved by scientific advances that have resulted in a rich and varied therapeutic landscape. Nevertheless, treatment limitations continue to drive innovation, and emer
Externí odkaz:
https://doaj.org/article/49b84b74635547b39a4cb8316ffbb30c
Autor:
Lea Graafen, Annekathrin Heinze, Nawid Albinger, Emilia Salzmann-Manrique, Franziska Ganß, Sabine Hünecke, Claudia Cappel, Sandra Wölke, Helena Donath, Jordis Trischler, Till-Martin Theilen, Christine Heller, Christoph Königs, Stephan Ehl, Peter Bader, Thomas Klingebiel, Jan-Henning Klusmann, Stefan Zielen, Ralf Schubert, Evelyn Ullrich
Publikováno v:
Frontiers in Immunology, Vol 15 (2024)
Ataxia telangiectasia (AT) is a rare autosomal-recessive disorder characterized by profound neurodegeneration, combined immunodeficiency, and an increased risk for malignant diseases. Treatment options for AT are limited, and the long-term survival p
Externí odkaz:
https://doaj.org/article/cd5c7ce260f64bc4ac1df5a9b6811eee
Autor:
Rosa Sonja Alesci, Georg Goldmann, Susan Halimeh, Katharina Holstein, Christoph Königs, Wolfgang Miesbach, Christian Pfrepper, Martin Olivieri
Publikováno v:
Frontiers in Medicine, Vol 11 (2024)
IntroductionThe disease burden and bleeding risk of patients with mild hemophilia may be underestimated. Their health-related quality of life (QoL) may be negatively impacted by insufficient treatment and bleed-related joint damage connected to a pot
Externí odkaz:
https://doaj.org/article/19f8d462bcaa46e585eedb6913bcf9bd
Autor:
Jan Astermark, Jan Blatný, Christoph Königs, Cédric Hermans, Victor Jiménez-Yuste, Daniel P. Hart
Publikováno v:
Therapeutic Advances in Hematology, Vol 14 (2023)
Recent advances in therapeutics are now providing a wide range of options for adults and children living with hemophilia. Although therapeutic choices are also increasing for the youngest individuals with severe disease, challenges remain about early
Externí odkaz:
https://doaj.org/article/69ffcda2103145819b48cedc4e3af5bb
Publikováno v:
eJHaem, Vol 2, Iss 4, Pp 805-808 (2021)
Externí odkaz:
https://doaj.org/article/0b822eb7922d451890d41dcda963503e
Publikováno v:
Southern African Journal of HIV Medicine, Vol 22, Iss 1, Pp e1-e3 (2021)
No abstract available.
Externí odkaz:
https://doaj.org/article/93bf507fcad14537b9fc417996462050
Autor:
Ahmad Faisal Karim, Anthony R. Soltis, Gauthaman Sukumar, Christoph Königs, Nadia P. Ewing, Clifton L. Dalgard, Matthew D. Wilkerson, Kathleen P. Pratt
Publikováno v:
Frontiers in Immunology, Vol 11 (2020)
Formation of pathological anti-FVIII antibodies, or “inhibitors,” is the most serious complication of therapeutic FVIII infusions, affecting up to 1/3 of severe Hemophilia A (HA) patients. Inhibitor formation is a classical T-cell dependent adapt
Externí odkaz:
https://doaj.org/article/82e845a0c3b84010b757baaccfdac88b
Autor:
Christoph Male, Nadine G. Andersson, Anne Rafowicz, Ri Liesner, Karin Kurnik, Kathelijn Fischer, Helen Platokouki, Elena Santagostino, Hervé Chambost, Beatrice Nolan, Christoph Königs, Gili Kenet, Rolf Ljung, Marijke van den Berg, PedNet study group
Publikováno v:
Haematologica, Vol 106, Iss 1 (2020)
The incidence of FIX inhibitors in severe hemophilia B (SHB) is not well defined. Frequencies of 3-5% have been reported but most studies to date were small, including patients with different severities, and without prospective follow-up for inhibito
Externí odkaz:
https://doaj.org/article/ffae13c2f6ad42f4ad673b17a83bc52a
Autor:
Delphine Bachelet, Thilo Albert, Cyprien Mbogning, Signe Hässler, Yuan Zhang, Stephan Schultze-Strasser, Yohann Repessé, Julie Rayes, Anna Pavlova, Behnaz Pezeshkpoor, Kerstin Liphardt, Julie E Davidson, Agnès Hincelin-Méry, Pierre Dönnes, Sébastien Lacroix-Desmazes, Christoph Königs, Johannes Oldenburg, Philippe Broët, ABIRISK consortium
Publikováno v:
PLoS ONE, Vol 14, Iss 6, p e0218258 (2019)
Replacement therapy in severe hemophilia A leads to factor VIII (FVIII) inhibitors in 30% of patients. Factor VIII gene (F8) mutation type, a family history of inhibitors, ethnicity and intensity of treatment are established risk factors, and were in
Externí odkaz:
https://doaj.org/article/e167617cea974ae693edaf5a173d15e0
Autor:
Christoph Königs, Stephan Schultze-Strasser, Andrea Quaiser, Konrad Bochennek, Dirk Schwabe, Thomas E. Klingebiel, Ulrike Koehl, Claudia Cappel, Udo Rolle, Peter Bader, Melanie Bremm, Sabine Huenecke, Shahrzad Bakhtiar
Publikováno v:
Frontiers in Pediatrics, Vol 6 (2018)
B lymphocytes are key players in humoral immunity, expressing diverse surface immunoglobulin receptors directed against specific antigenic epitopes. The development and profile of distinct subpopulations have gained awareness in the setting of primar
Externí odkaz:
https://doaj.org/article/7c57b71292b14b7c9ddd8ac008f19bd0